XORTX Therapeutics (XRTX) Operating Leases (2022 - 2026)
XORTX Therapeutics' (XRTX) quarterly Operating Leases came in at $11510.0 in Q4 2023, little changed YoY from $11483.7 in Q4 2022, and little changed on a QoQ basis from $11483.7 in Q4 2022.
XORTX Therapeutics (XRTX) Operating Leases (2022 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 2 years of Operating Leases data on file, last reported at $11510.0 in Q4 2023.
- Quarterly Operating Leases changed 0.23% year-over-year to $11510.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $11510.0 (changed 0.23% YoY) and the FY2023 annual result came in at $11510.0, changed 0.01% from the prior year.
- Operating Leases held at $11510.0 in Q4 2023, from $11483.7 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $48001.6 in Q2 2022 to a low of $11483.7 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,056.00 |
| Dec 31, 2025 | 37,287.00 |
| Sep 30, 2025 | 59,094.00 |
| Jun 30, 2025 | 80,473.00 |
| Mar 31, 2025 | 15,662.00 |
| Dec 31, 2024 | 38,785.00 |
| Sep 30, 2024 | 61,468.00 |
| Jun 30, 2024 | 83,706.00 |
| Dec 31, 2023 | 11,510.00 |
| Dec 31, 2022 | 11,483.73 |
| Sep 30, 2022 | 29,609.44 |
| Jun 30, 2022 | 48,001.65 |